CompletedPhase 3NCT00006363
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Studying Acute basophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Jonathan Kolitz, MDCancer and Leukemia Group B
- Intervention
- cytarabine(drug)
- Enrollment
- 720 enrolled
- Eligibility
- 15-59 years · All sexes
- Timeline
- 2000
Study locations (1)
- Cancer and Leukemia Group B, Chicago, Illinois, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006363 on ClinicalTrials.govOther trials for Acute basophilic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT01627041Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT00898456Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology